A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma — YATAGARASU

Salivary Gland Neoplasms Clinical Trial

Official title:
An Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Apalutamide in Combination With Gonadotropin-releasing Hormone (GnRH) Agonist in Subjects With Locally Advanced or Recurrent/Metastatic and Androgen Receptor (AR) Expressing Salivary Gland Carcinoma

Status Active, not recruiting

Clinical Trial Summary

The purpose of the study is to evaluate the overall response rate (ORR) of apalutamide in combination with a gonadotropin-releasing hormone (GnRH) agonist in participants with androgen receptor (AR) expressing locally advanced or recurrent/metastatic salivary gland carcinoma (SGC).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Salivary Gland Neoplasms

Clinical Trial Details

NCT number	NCT04325828
Study type	Interventional
Source	Janssen Pharmaceutical K.K.
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	April 7, 2020
Completion date	September 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00568438` - Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample
Terminated	`NCT04644315` - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors	Phase 2
Recruiting	`NCT05087706` - Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）
Completed	`NCT03602079` - Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene	Phase 1/Phase 2
Completed	`NCT05390294` - Survival With Patients Treated With Salivary Gland Cancer
Recruiting	`NCT03942380` - Cell-free Tumor DNA in Head and Neck Cancer Patients	N/A
Withdrawn	`NCT04832438` - 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma	Phase 2